Key Points
- CEO Martine Rothblatt sold 9,500 shares of United Therapeutics for about $5.44 million on Monday, cutting her stake by 19%. The sale was disclosed in an SEC filing.
- United Therapeutics recently missed quarterly expectations, reporting earnings of $5.82 per share versus the $7.00 consensus and revenue of $781.5 million versus estimates of $797.4 million. Revenue also declined 1.6% from a year earlier.
- Analysts remain generally positive on the stock, with a consensus “Moderate Buy” rating and an average target price of $619.42. Recent broker updates included both price-target adjustments and reiterated buy/outperform ratings.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $573.10, for a total transaction of $5,444,450.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company's stock, valued at approximately $23,218,000.30. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
United Therapeutics Stock Performance
Shares of UTHR opened at $581.74 on Wednesday. The firm has a market cap of $24.69 billion, a price-to-earnings ratio of 21.47, a PEG ratio of 1.80 and a beta of 0.60. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The firm has a 50 day moving average price of $553.65 and a 200-day moving average price of $504.46.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company's revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.63 earnings per share. As a group, equities research analysts predict that United Therapeutics Corporation will post 27.64 earnings per share for the current year.
Key Stories Impacting United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: United Therapeutics presented new data from TETON-1, ADVANCE OUTCOMES, and additional research in pulmonary hypertension and pulmonary fibrosis at ATS 2026, which could support the company’s long-term pipeline outlook. Article link
- Neutral Sentiment: Analysts remain broadly constructive, with several recent price target increases and a consensus “Moderate Buy” rating, suggesting the stock still has support from Wall Street despite recent volatility.
- Negative Sentiment: CEO Martine A. Rothblatt sold 9,500 shares, reducing her stake by 19%, and CFO James Edgemond sold 10,000 shares, cutting his holdings by 34.6%. Insider selling can weigh on sentiment because investors may read it as management taking profits after the stock’s strong run. CEO filing CFO filing
- Negative Sentiment: The company also recently reported weaker-than-expected quarterly results, missing on both earnings and revenue, which may still be pressuring valuation even after the stock’s rebound.
Analyst Ratings Changes
A number of brokerages have recently weighed in on UTHR. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an "outperform" rating for the company in a report on Thursday, May 7th. Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price objective for the company. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, March 12th. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $619.42.
View Our Latest Research Report on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC increased its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new position in United Therapeutics during the 4th quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
